PharmaNest accelerates the discovery and development of novel anti-fibrotic therapies and related diagnostics
Fibrosis Kills
Fibrosis causes 45% of all deaths, yet early disease is missed, diagnosis is subjective, and monitoring is imprecise.
With few targeted therapies and no quantitative biomarkers, the field lacks the tools needed to detect change, guide care, and develop new treatments.
From Idea to Impact
PharmaNest started with a simple belief: fibrosis isn’t just a scar — it’s a dynamic, measurable signature of tissue remodeling.
That insight led to FibroNest™, the first platform to quantify every collagen fiber from conventional digital pathology images, decode its architecture, and turn microscopic structure into actionable biomarkers for drug development and clinical insight.
We then created FibroMAP™, moving beyond measurement to meaning. By clustering millions of fibers into phenotypic patterns, FibroMAP uncovers fibrotypes that stratify patients, reveal mechanism of action, and predict outcomes.
As the field recognizes that fibrosis can be reversed across organs, our biomarkers are built to accelerate the next generation of targeted antifibrotic therapies.
FibroMAP
Single-Fiber Spatial Histology for Phenotypic Mapping of Fibrosis and Fibrotypes discovery
FibroNest
Quantitative Digital Pathology Platform for Fibrosis Assessment and Biomarker Discovery
FibroNest™ is PharmaNest’s quantitative digital pathology platform for fibrosis analysis.
From conventional Digital Pathology images, it extracts hundreds of single-fiber and tissue-level parameters from histology slides to measure fibrosis and its remodeling with precision.
Using AI-assisted image segmentation and feature extraction, it quantifies the multiple phenotypes of fibrosis across tissue compartments.
FibroNest provides continuous, reproducible biomarkers aligned with clinical outcomes. It is used from preclinical to clinical studies to quantify disease progression and therapeutic efficacy
FibroMAP™ is PharmaNest’s single-fiber spatial histology platform.
FibroMAP applies sophisticated computational methods to cluster millions of collagen fibers, and, when available, complementary spatial modalities data, to reveal distinct “fibrotypes
FibroMAP enables visualization, stratification, and comparison of fibrotypes across tissues, treatments, and disease models.
Much like singe-cell analysis, single-fiber analysis and FibroMAP are poised to revolutionize the study of Fibrosis
Why our Clients Choose Us?
We help our clients accelerate and improve their drug development efforts by improving:
MOA elucidation
Patient stratification
Measurement of treatment response
Support of antifibrotic claims
Holistic evaluation of therapeutic effects
About PharmaNest
PharmaNest is a digital pathology and AI company specializing in the quantitative analysis of fibrosis and tissue remodeling across preclinical and clinical research. Our proprietary FibroNest™ and FibroMAP™ platforms transform histological slides into rich, multidimensional datasets, enabling precise measurement of collagen architecture, inflammation, and tissue repair at the single-fiber level.
By integrating advanced image analytics, spatial phenotyping, and machine learning, PharmaNest provides reproducible, quantitative biomarkers that bridge preclinical models and human trials. Our technologies are trusted by leading pharmaceutical and academic partners worldwide to accelerate drug development in MASH, IBD, Crohn’s disease, PSC, EoE, cardiac, and pulmonary fibrosis.
Through scientific rigor, innovation, and collaboration, PharmaNest is redefining how fibrosis is quantified—bringing clarity, precision, and translational value to the study of tissue remodeling and disease progression.
What can we help you with today ?
Click the button below or write to info@pharmanest.com